Table 5.

Hazard ratio (95% CI) for progression-free and overall survival among ovarian cancer patients according to A and non-A blood type

	Progression-free survival			Overall survival
	Blood type		P value for Interaction	Blood type		P value for Interaction
	Non-Type A	Type A		Non-Type A	Type A
	HR (95%CI)†	HR (95%CI)†		HR (95%CI)†	HR (95%CI)†
All patients	1.00 (Ref)	0.99 (0.75-1.29)		1.00 (Ref)	1.07 (0.81-1.41)
FIGO stage			0.10			0.17
I-II	1.00 (Ref)	1.43 (0.80-2.55)		1.00 (Ref)	1.44 (0.75-2.74)
III-IV	1.00 (Ref)	0.90 (0.66-1.22)		1.00 (Ref)	0.99 (0.73-1.35)
Histological type			0.54			0.34
Serous	1.00 (Ref)	1.04 (0.77-1.40)		1.00 (Ref)	1.15 (0.85-1.56)
Non-serous	1.00 (Ref)	0.76 (0.37-1.55)		1.00 (Ref)	0.76 (0.38-1.55)
Residual disease			0.60			0.40
None detectable	1.00 (Ref)	1.08 (0.72-1.61)		1.00 (Ref)	1.29 (0.84-1.99)
≤ 1 cm	1.00 (Ref)	0.73 (0.41-1.30)		1.00 (Ref)	0.91 (0.52-1.61)
> 1 cm	1.00 (Ref)	1.09 (0.67-1.79)		1.00 (Ref)	0.92 (0.56-1.51)
Comorbidity			0.69			0.79
Yes	1.00 (Ref)	1.09 (0.44-2.70)		1.00 (Ref)	1.11 (0.76-1.61)
No	1.00 (Ref)	0.92 (0.62-1.36)		1.00 (Ref)	1.01 (0.66-1.54)

CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio.

† HRs (95% CIs) for progression-free and overall survival were estimated by using multivariable proportional hazard models that were adjusted for age at diagnosis, FIGO, residual disease, performance status, ascites, and grading.